Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A

Oncogene

Volumn 15, Issue 8, 1997, Pages 953-960

  Uenou, Naoto T ^a   Yu, Dihua ^a   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast neoplasms; E1A; Gene therapy; HER 2 neu; Paclitaxel

Indexed keywords

DOCETAXEL; PACLITAXEL;

ADENOVIRUS 5; ANIMAL CELL; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5;

EID: 0030880078     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1201250     Document Type: Article

References (52)

1. Almandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP and Kraus MH. (1995). Oncogene, 10, 1813-1821.
2. Bargmann CI, Hung MC and Weinberg RA. (1986). Cell, 45, 649-657.
3. Bargmann CI and Weinberg RA. (1988). Proc. Natl. Acad. Sci. USA, 85, 5394-5398.
4. Chang JY, Xia WY, Shao RP and Hung MC. (1996). Oncogene, 13, 1405-1412.
5. Chen H and Hung MC. (1997). J. Biol. Chem., 272, 6101-6104.
6. Coussens L, Yang FT, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A and Ullrich A. (1985). Science, 230, 1132-1139.
7. Davidson NE, Gelmann EP, Lippman ME and Dickson RB. (1987). Mol. Endocrinology, 1, 216-223.
8. Frisch SM and Dolter KE. (1995). Cancer Res., 55, 5551-5555.
9. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderbörgh SJ, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Marinez-Tello F, Tiltman F, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J and Senn HJ. (1992). J. Clin. Oncol., 10, 1049-1056.
10. Hansen MB, Nielsen SE and Berg K. (1989). J. Immunol. Meth., 119, 203-210.
11. Hata Y, Sandler A, Loehrer PJ, Sledge GJ and Weber G. (1994). Oncol. Res., 6, 19-24.
12. Horwitz SB. (1994). Ann. Oncol., 5 Suppl 6, S3-S6.
13. Jones N and Shenk T. (1979). Cell., 17, 683-689.
14. Kiyokawa N, Yan DH, Brown ME and Hung MC. (1995). Proc. Natl. Acad. Sci. USA, 92, 1092-1096.
15. Kraus MH, Popescu NC, Amsbaugh SC and King CR. (1987). EMBO J., 6, 605-610.
16. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD and Mixson AJ. (1995). Hum. Gene Ther., 6, 395-405.
17. Liu TJ, el-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL and Clayman GL. (1995). Cancer Res., 55, 3117-3122.
18. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H and Clayman GL. (1994). Cancer Res., 54, 3662-3667.
19. Lowe SW, Ruley HE, Jacks T and Housman DE. (1993). Cell, 74, 957-967.
20. Matin A, Cheng KL, Suen TC and Hung MC. (1990). Oncogene, 5, 111-116.
21. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BM and Carney DN. (1991). Cancer Res., 51, 3296-3306.
22. Miller SJ and Hung MC. (1995). Oncology Reports, 2, 497-503.
23. Nevins JR. (1995). Curr. Top. Microbiol. Immunol. 199: 25-32.
24. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG and Shoyab M. (1993). Proc. Natl. Acad. Sci. USA, 90, 1746-1750.
25. Runnenbaum IB, Nagarajan M, Bowman M, Soto D and Sukumar S. (1991). Proc. Natl. Acad. Sci. USA, 88, 10657-10661.
26. Sanchezprieto R, Quintanilla M, Cano A, Lleonart M, Martin P, Anaya A and Cajal S. (1996). Oncogene, 13, 1083-1092.
27. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang FT, Francke U, Ullrich A and Coussens L. (1985). Science, 229, 976-978.
28. Schiff PB and Horwitz SB. (1980). Proc. Natl. Acad. Sci. USA, 11, 1561-1565.
29. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL. (1987). Science, 235, 177-182.
30. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF. (1989). Science, 244, 707-712.
31. Stern DF, Kamps MP and Cao H. (1988). Mol. Cell. Biol., 8, 3969-3973.
32. Stratford PL, Makeh I, Perricaudet M and Briand P. (1992). J. Clin. Invest., 90, 626-630.
33. Toikkanen S, Helin H, Isola J and Joensuu H. (1992). J. Clin. Oncol., 10, 1044-1048.
34. Tsai CM, Perng RP, Cheng MH, Jan YH, Hung MC, Ku TY and Chang KT. (1994). J. Natl. Cancer Inst., 86, 1018-1020.
35. Tsai CM, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK and Hung MC. (1995). J. Natl. Cancer Inst., 87, 682-684.
36. Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu N, Yayon A, Wen D et al. (1994). J. Biol. Chem., 269, 25226-25233.
37. van de Vijver M, van der Bersselaar R, Devilee P, Cornelisse C, Peterse J and Nusse R. (1987). Mol. Cell. Biol., 7, 2019-2023.
38. Webb JL. (1963). Enzyme and metabolic inhibitor. Academic Press, New York. 1, 507-510.
39. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T and Toyoshima K. (1986). Nature, 319, 230-234.
40. Yan DH, Chang LS and Hung MC. (1991). Oncogene, 6, 343-345.
41. Yu D, Hamada J, Zhang H, Nicolson GL and Hung MC. (1992). Oncogene, 7, 2263-2270.
42. Yu D, Matin A, Hinds PW and Hung MC. (1994a). Cell Growth Differ., 5, 431-438.
43. Yu D, Matin A, Xia W, Sorgi F, Huang L and Hung MC. (1995). Oncogene, 11, 1383-1388.
44. Yu D, Shi D, Scanlon M and Hung MC. (1993a). Cancer Res., 53, 5784-5790.
45. Yu D, Suen TC, Yan DH, Chang LS and Hung MC. (1990). Proc. Natl. Acad. Sci. USA, 87, 4499-4503.
46. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL and Hung MC. (1994b). Cancer Res., 54, 3260-3266.
47. Yu D, Wolf JK, Scanlon M, Price JE and Hung MC. (1993b). Cancer Res., 53, 891-898.
48. Yu DH and Hung MC. (1991). Oncogene, 6, 1991-1996.
49. Yu DH, Liu BL, Tan M, Li JZ, Wang SS and Hung MC. (1996). Oncogene, 13, 1359-1365.
50. Yu DH, Scorsonc K and Hung MC. (1991). Mol. Cell Biol., 11, 1745-1750.
51. Zhung LS and Hung MC. (1996). Oncogene, 12, 571-516.
52. Zhang Y, Yu D, Xia W and Hung MC. (1995). Oncogene, 10, 1947-1954.